Using Fucoidan to Reduce Lung Damage from Radiation Therapy
A Phase II Trial of Oligo-Fucoidan in Radiation Induced Ling Injury
This study is testing if Fucoidan can help reduce lung damage and heart problems in lung cancer patients receiving radiation therapy to improve their quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 20 Years to 90 Years |
| Sex | All |
| Sponsor | Taipei Medical University WanFang Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Taipei, Please Select) |
| Trial ID | NCT05616507 on ClinicalTrials.gov |
What this trial studies
This project aims to evaluate the effectiveness of Fucoidan in reducing lung damage and heart toxicity caused by radiation therapy in lung cancer patients. Fucoidan, which is FDA approved for treating angina, will be tested in a clinical setting to see if it can improve the quality of life and treatment outcomes for patients undergoing radiation therapy. The study will include both veterans and non-veterans, focusing on those with a Karnofsky performance status greater than 70. The goal is to translate promising animal study results into human applications, potentially enhancing the efficacy of radiation therapy.
Who should consider this trial
Good fit: Ideal candidates are men and women aged 20-90 who are undergoing radiation therapy for lung cancer.
Not a fit: Patients who do not require or are unwilling to undergo radiation therapy for lung cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the quality of life and treatment outcomes for lung cancer patients receiving radiation therapy.
How similar studies have performed: Previous studies in laboratory animals have shown promising results in reducing lung fibrosis and heart toxicity with Fucoidan, but this approach is novel in human applications.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Ages Eligible for Study: 20-90 years old 2. Men and women undergoing radiation therapy for lung cancer，no matter the radiation therapy is for curing or for palliating. 3. Karnofsky performance status，KPS \> 70 4. Absolute Neutrophils \> 1000/mm\^3 5. Platelets \> 75,000/mm\^3 6. Hematocrit \> 25%. 7. Liver and kidney function tests will be within normal range 8. Baseline blood pressure will be systolic \> 110 mmHg sitting Exclusion Criteria: 1. Patients who get lung cancer but no need or without the willingness of radiation therapy 2. Patients who are taking antiHTN drugs 3. Women of pregnant, lactating, childbearing potential, or with the intention of becoming pregnant 4. Patients who are presently participating in another clinical study (except for follow-up surveys for study outcomes) 5. Patients who are judged to be ineligible for study entry by the investigator or subinvestigator
Where this trial is running
Taipei, Please Select
- Szu-Yuan Wu — Taipei, Please Select, Taiwan (Recruiting)
Study contacts
- Study coordinator: Szu-Yuan Wu
- Email: szuyuanwu5399@gmail.com
- Phone: +886910603955
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.